Clearmind Medicine INC. 6-K Filing

Key Financial Figures

• $0.12 — Offering”) at a purchase price of $0.12 per Common Share and $0.1199 per Pre-Fu
• $0.1199 — ase price of $0.12 per Common Share and $0.1199 per Pre-Funded Warrant. The Pre-Funded
• $0.0001 — ely exercisable at an exercise price of $0.0001 per Common Share, subject to adjustment
• $1.294 million — ompany are expected to be approximately $1.294 million. The Company expects to use the net pro

Filing Documents

• ea0267257-6k_clearmind.htm (6-K) — 20KB
• ea026725701ex5-1_clearmind.htm (EX-5.1) — 22KB
• ea026725701ex5-2_clearmind.htm (EX-5.2) — 13KB
• ea026725701ex10-1_clearmind.htm (EX-10.1) — 187KB
• ea026725701ex10-2_clearmind.htm (EX-10.2) — 100KB
• ex5-1_001.jpg (GRAPHIC) — 3KB
• ex5-1_002.jpg (GRAPHIC) — 1KB
• ex5-2_001.jpg (GRAPHIC) — 3KB
• 0001213900-25-115110.txt ( ) — 353KB

Forward Looking Statements

Forward Looking Statements This Report of on Form 6-K contains statements which constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. These forward looking statements are based upon the Company’s present intent, beliefs or expectations, but forward looking statements are not guaranteed to occur and may not occur for various reasons, including some reasons which are beyond the Company’s control. For example, this Report states that the Offering is expected to close on or about November 26, 2025. In fact, the closing of the Offering is subject to various conditions and contingencies as are customary in securities purchase agreements in the United States. If these conditions are not satisfied or the specified contingencies do not occur, this Offering may not close. For this reason, among others, you should not place undue reliance upon the Company’s forward looking statements. Except as required by law, the Company undertakes no obligation to revise or update any forward looking statements in order to reflect any event or circumstance that may arise after the date of this Report on Form 6-K. 1 EXHIBIT INDEX Exhibit No. 5.1 Opinion of Daniel N. Bloch, Canadian counsel to the Company 5.2 Opinion of Greenberg Traurig, P.A., U.S. counsel to the Company 10.1 Form of Securities Purchase Agreement 10.2 Form of Pre-Funded Warrant 23.1 Consent of Daniel N. Bloch (included in Exhibit 5.1) 23.2 Consent of Greenberg Traurig, P.A. (included in Exhibit 5.2) 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Clearmind Medicine, Inc. (Registrant) Date: November 26, 2025 By: /s/ Adi Zuloff-Shani Name: Adi Zuloff-Shani Title: Chief Executive Officer 3

View Full Filing

View this 6-K filing on SEC EDGAR